Apricus Biosciences' CEO to Present at the Stifel Nicolaus 2012 Healthcare Conference

Apricus Biosciences, Inc. 

22.08.2012 21:00
---------------------------------------------------------------------------

SAN DIEGO, 2012-08-22 21:00 CEST (GLOBE NEWSWIRE) --
Apricus Biosciences, Inc. ('Apricus Bio' or the 'Company') (Nasdaq:APRI)
(http://www.apricusbio.com) announced today that Bassam Damaj, Ph.D., President
and Chief Executive Officer, will present at the Stifel Nicolaus 2012
Healthcare Conference, being held at The Four Seasons in Boston, Massachusetts.
Apricus Biosciences' presentation will take place on September 6, 2012 at
2:40pm Eastern Time. 

About Apricus Biosciences, Inc.

Apricus Bio (Nasdaq:APRI) is a pharmaceutical company that develops and markets
innovative treatments that help large patient populations across numerous,
high-demand therapeutic classes. The Company has four approved products and has
developed a strong pipeline of multiple late-stage product candidates. With
commercial operations in both the U.S. and Europe (France), Apricus Bio
generates revenues and growth from sales of its commercial products and by
out-licensing, in certain territories, its pipeline products and NexACT(r)
technology. 

Apricus Bio's growth strategy is to acquire, develop, and commercialize new
products through strategic partnerships. The Company currently has commercial
partnerships with multiple large pharmaceutical companies including Novartis,
Abbott Laboratories, Sandoz, Warner Chilcott, Wockhardt, and Bracco, and
co-promotes multiple products in France. 

Apricus Bio is headquartered in San Diego, CA and is publicly traded on the
NASDAQ Capital Market under the ticker symbol APRI. 

For further information on Apricus Bio, visit http://www.apricusbio.com, and
for information on its subsidiary please visit http://www.nexmedusa.com. You
can also receive information at http://twitter.com/apricusbio. 


         Apricus Bio Investor Relations:
         
         David Pitts
         Argot Partners
         212-600-1902
         david@argotpartners.com
News Source: NASDAQ OMX



22.08.2012 Dissemination of a Corporate News, transmitted by DGAP - 
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------
 
Language:     English
Company:      Apricus Biosciences, Inc.
              
               
              United States
Phone:        
Fax:          
E-mail:       
Internet:     
ISIN:         US9901429525
WKN:          
 
End of Announcement                             DGAP News-Service
 
---------------------------------------------------------------------------